This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belfiore, A. Articles by Vigneri, R. Search for Related Content PubMed PubMed Citation Articles by Belfiore, A. Articles by Vigneri, R.

Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases¹

Istituto di Medicina Interna e di Malattie Endocrine e del Metabolismo, Cattedra di Endocrinologia, University of Catania; Servizio di Anatomia Patologica, Ospedale V. Emanuele II (P.G., G.R., A.F.); and Cattedra di Chirurgia, University of Catania (O.I.), Catania; and Dipartimento di Scienze Biomediche ed Oncologia, University of Torino (M.F.D.R., P.C.), Torino, Italy

Address all correspondence and requests for reprints to: Antonino Belfiore, M.D., Istituto di Medicina Interna e di Malattie Endocrine e del Metabolismo, Cattedra di Endocrinologia, Ospedale Garibaldi, Piazza S. Maria di Gesù 1, 95123 Catania, Italy. E-mail: segmeint{at}mbox.unict.it

To investigate the clinical impact of Met/hepatocyte growth factor receptor (HGF-R) expression in thyroid cancer we studied 163 thyroid carcinomas (129 papillary, 21 follicular, and 13 anaplastic) from patients followed-up for 25–147 months postthyroidectomy. Forty-nine thyroid adenomas were also studied. Met/HGF-R expression was evaluated by semiquantitative immunohistochemistry, measuring both the proportion (scale of 0–5) and the intensity (scale, 0–5) of stained cells and calculating a total score (scale of 0–10).

Met/HGF-R was absent in the normal thyroid tissue, absent or focally expressed in follicular and anaplastic tumors, and expressed at various levels in most papillary carcinomas, including microcarcinomas. Papillary carcinomas were thus categorized as having negative/low Met/HGF-R (n = 50; total score, 5) or high Met/HGF-R expression (n = 70; total score, >5). High Met/HGF-R was inversely associated with vascular invasion (P = 0.0308), but not with other prognostic factors. Negative/low Met/HGF-R expression was the most effective predictor by multivariate Cox analysis of distant metastases (hazard ratio = 9.71; P = 0.0036), higher than extrathyroid invasion (hazard ratio = 4.25; P = 0.0181), age (45 vs. >45 yr; hazard ratio = 3.99; P = 0.0099), and vascular invasion (hazard ratio = 3.19; P = 0.0358). These findings suggest a role for Met/HGF-R in papillary thyroid cancer and its clinical use to select patients with a high risk of distant metastases.

This article has been cited by other articles:

				J. A Woyach and M. H Shah New therapeutic advances in the management of progressive thyroid cancer Endocr. Relat. Cancer, September 1, 2009; 16(3): 715 - 731. [Abstract] [Full Text] [PDF]

				L. Toschi and P. A. Janne Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946. [Abstract] [Full Text] [PDF]

				K. Fujarewicz, M. Jarzab, M. Eszlinger, K. Krohn, R. Paschke, M. Oczko-Wojciechowska, M. Wiench, A. Kukulska, B. Jarzab, and A. Swierniak A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping Endocr. Relat. Cancer, September 1, 2007; 14(3): 809 - 826. [Abstract] [Full Text] [PDF]

				C. Ghoneim, M. Soula-Rothhut, C. Blanchevoye, L. Martiny, F. Antonicelli, and B. Rothhut Activating Transcription Factor-1-mediated Hepatocyte Growth Factor-induced Down-regulation of Thrombospondin-1 Expression Leads to Thyroid Cancer Cell Invasion J. Biol. Chem., May 25, 2007; 282(21): 15490 - 15497. [Abstract] [Full Text] [PDF]

				C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198. [Abstract] [Full Text] [PDF]

				O. L. Griffith, A. Melck, S. J.M. Jones, and S. M. Wiseman Meta-Analysis and Meta-Review of Thyroid Cancer Gene Expression Profiling Studies Identifies Important Diagnostic Biomarkers J. Clin. Oncol., November 1, 2006; 24(31): 5043 - 5051. [Abstract] [Full Text] [PDF]

				R. Mineo, A. Costantino, F. Frasca, L. Sciacca, S. Russo, R. Vigneri, and A. Belfiore Activation of the Hepatocyte Growth Factor (HGF)-Met System in Papillary Thyroid Cancer: Biological Effects of HGF in Thyroid Cancer Cells Depend on Met Expression Levels Endocrinology, September 1, 2004; 145(9): 4355 - 4365. [Abstract] [Full Text] [PDF]

				G. Pellegriti, C. Scollo, G. Lumera, C. Regalbuto, R. Vigneri, and A. Belfiore Clinical Behavior and Outcome of Papillary Thyroid Cancers Smaller than 1.5 cm in Diameter: Study of 299 Cases J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3713 - 3720. [Abstract] [Full Text] [PDF]

				H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]

				V. Vella, G. Pandini, L. Sciacca, R. Mineo, R. Vigneri, V. Pezzino, and A. Belfiore A Novel Autocrine Loop Involving IGF-II and the Insulin Receptor Isoform-A Stimulates Growth of Thyroid Cancer J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 245 - 254. [Abstract] [Full Text] [PDF]

				V Vella, L Sciacca, G Pandini, R Mineo, S Squatrito, R Vigneri, and A Belfiore The IGF system in thyroid cancer: new concepts Mol. Pathol., June 1, 2001; 54(3): 121 - 124. [Abstract] [Full Text]

				R. E. Gardner, R. M. Tuttle, K. D. Burman, S. Haddady, C. Truman, Y. H. Sparling, L. Wartofsky, R. B. Sessions, and M. D. Ringel Prognostic Importance of Vascular Invasion in Papillary Thyroid Carcinoma Arch Otolaryngol Head Neck Surg, March 1, 2000; 126(3): 309 - 312. [Abstract] [Full Text] [PDF]

				Loss of Heterozygosity of the Long Arm of Chromosome 7 in Follicular and Anaplastic Thyroid Cancer, but Not in Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3235 - 3240. [Abstract] [Full Text] [PDF]

				G. Pellegriti, A. Belfiore, D. Giuffrida, L. Lupo, and R. Vigneri Outcome of Differentiated Thyroid Cancer in Graves' Patients J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2805 - 2809. [Abstract] [Full Text]